Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dopamine D3 Receptor Occupancy in Bipolar Depression by Cariprazine
NCT05060549Phase 4Withdrawn
- Sponsor
- New York State Psychiatric Institute
- Start
- Jan 2026
- Primary completion
- May 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of cariprazine in bipolar disorder (BD), sponsored by New York State Psychiatric Institute. Planned start Jan 2026; status: withdrawn.
02
Drugs
cariprazine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT05060549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05060549.